Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

NAD+ regulatory status

Current status of NAD+ in the United States: In FDA review (Category 1). In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of NAD+?

Regulatory: In FDA review (Category 1)WADA: Not WADA prohibitedVerified: Verified Sep 29, 2026
FDA and compounding
NAD+ (nicotinamide adenine dinucleotide) is not an FDA approved drug. As of the last verification date it is in FDA's 503A Category 1, the list of nominated bulk substances still under evaluation that FDA has not flagged as a significant safety risk. Under FDA's interim policy, FDA does not intend to act against a state-licensed 503A pharmacy that compounds with a Category 1 substance if the bulk ingredient comes from FDA-registered manufacturers with a valid certificate of analysis and the other 503A conditions are met. That protection lasts until FDA decides on listing by final rule or removes NAD+ from Category 1. One salt form, the beta disodium salt trihydrate, is in Category 3 and is not covered. State boards may add their own limits.
WADA
Not WADA prohibited
Access path
  1. Over the counter dietary supplement precursors (nicotinamide riboside, nicotinamide mononucleotide), no prescription needed.
  2. Prescription from a licensed provider filled by a 503A compounding pharmacy for injectable NAD+, where the state board permits it.
  3. Clinic or telehealth programs offering NAD+ infusions or injections.

Full NAD+ page: evidence, dosing in the literature, and sources

How has the status of NAD+ changed over time?

No dated regulatory event has been recorded for NAD+. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for NAD+ and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  2. [2]WADA Prohibited ListWADA, 2026